A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis

Basit Öğe Kaydı
dc.contributor.authorGül C.
dc.contributor.authorGül A.
dc.contributor.authorKarakavuk T.
dc.contributor.authorErkunt Alak S.
dc.contributor.authorKarakavuk M.
dc.contributor.authorCan H.
dc.contributor.authorDeğirmenci Döşkaya A.
dc.date.accessioned2024-08-31T07:42:30Z
dc.date.available2024-08-31T07:42:30Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractToxoplasma gondii is an obligate intracellular parasite that can infect a variety of mammals including humans and causes toxoplasmosis. Unfortunately, a protective and safe vaccine against toxoplasmosis hasn't been developed yet. In this study, we developed a DNA vaccine encoding the SRS13 protein and immunized BALB/c mice thrice with pVAX1-SRS13 through the intramuscular route (IM) or intradermally using an electroporation device (ID + EP). The immunogenicity of pVAX1-SRS13 was analyzed by ELISA, Western blot, cytokine ELISA, and flow cytometry. The protective efficacy of the pVAX1-SRS13 was investigated by challenging mice orally with T. gondii PRU strain tissue cysts. The results revealed that pVAX1-SRS13 administered through IM or ID + EP routes induced high level of anti-SRS13 IgG antibody responses (P = 0.0037 and P < 0.0001). The IFN-? level elicited by the pVAX1-SRS13 (ID + EP) was significantly higher compared to the control group (P = 0.00159). In mice administered with pVAX1-SRS13 (ID + EP), CD8+ cells secreting IFN-? was significantly higher compared to pVAX1-SRS13 (IM) (P = 0.0035) and the control group (P = 0.0068). Mice vaccinated with the SRS13 DNA vaccine did not induce significant IL-4 level. Moreover, a significant reduction in the number of tissue cysts and the load of T. gondii DNA was detected in brains of mice administered with pVAX1-SRS13 through ID + EP and IM routes compared to controls. In conclusion, the SRS13 DNA vaccine was found to be highly immunogenic and confers strong protection against chronic toxoplasmosis. © 2024 Elsevier Ltden_US
dc.description.sponsorshipScientific Research Projects Branch Directorate of Ege University, (22890)en_US
dc.identifier.doi10.1016/j.vaccine.2024.06.032
dc.identifier.issn0264-410X
dc.identifier.scopus2-s2.0-85196007112en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2024.06.032
dc.identifier.urihttps://hdl.handle.net/11454/103910
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofVaccineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectDNA vaccineen_US
dc.subjectElectroporationen_US
dc.subjectSRS13en_US
dc.subjectT. gondii PRU strainen_US
dc.subjectToxoplasma gondiien_US
dc.subjectToxoplasmosisen_US
dc.titleA novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu